Now, the technology is making headlines again in cancer treatment. For the first time, a personalised mRNA cancer vaccine has ...

A new review synthesizes preclinical and clinical evidence showing that lipid nanoparticle biodistribution, mRNA persistence, ...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...

Novel hybrid polymer nanocarriers enable effective vaccine delivery in the lungs and the targeted activation of immune cells. “Effective mucosal vaccination via inhalation requires carrier systems ...

Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.

Denise Fitzsimmons knew that removing the fast-growing lump above her eyebrow in 2024 didn’t eliminate the possibility that her melanoma could return. But a clinical trial at Penn Medicine offered the ...

Moderna (MRNA) shares ripped higher on Friday as reports of a planned U.S. initiative to accelerate cancer vaccine ...

The FDA’s approval of an mRNA flu shot presents a new, long-awaited option—and raises big questions about the future of flu ...

The FDA has approved mFlusiva, the first mRNA flu vaccine, for adults ages 50 to 64, but the CDC has not added it to its recommended list amid legal uncertainties and disruptions to the federal ...

For some older adults, the flu vaccine could look a little different this year. In August, the US Food and Drug Administration approved the nation’s first mRNA-based flu vaccine for use in people 50 ...